Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Erika J CrosbyChaitanya R AcharyaAnthony-Fayez HaddadChristopher A RabiolaGangjun LeiJun-Ping WeiXiao-Yi YangTao WangCong-Xiao LiuKay-Uwe WagnerWilliam J MullerLewis A ChodoshGloria BroadwaterTerry HyslopJonathan H ShepherdDaniel P HollernXiaping HeCharles M PerouShengjie ChaiBenjamin K AshbyBenjamin G VincentJoshua C SnyderJeremy ForceMichael A MorseHerbert Kim LyerlyZachary Conrad HartmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combining oncogenic driver targeted vaccines with selective ICB offers a rational paradigm for precision immunotherapy, which we are clinically evaluating in a phase II trial (NCT03632941).